Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Biologics Watch Canada, U.S. Treatments Of Follow-Ons

This article was originally published in PharmAsia News

Executive Summary

India's biologics industry expects the United States and Canada, acting separately, to propose regulations of biologics similar to the practice already underway in Europe. Canada has a guidance document available and expects its second guidance, on subsequent entry biologics, to be released in March. U.S. FDA also has drafted a proposed way of treating follow-on biologics, but that is still in the internal review process. Both Canada and the U.S. are expected to follow the European model. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts